



Synthesis of a new transition-state analog of the sialyl donor. Inhibition of sialyltransferases

Hongbin Sun, Jingsong Yang, Katie E. Amaral and Benjamin A. Horenstein*

Department of Chemistry, University of Florida, Gainesville, FL 32611-7200, USA

Received 22 December 2000; accepted 2 February 2001

Abstract—A new class of glycosyltransferase inhibitor has been designed and synthesized. The designed inhibitors **3a/3b** provide conformational mimicry of the transition state in sialyltransfer reactions. The key synthetic steps involve a Meinwald rearrangement and a palladium-catalyzed carbonylation reaction. The results of kinetic studies show that **3a/3b** exhibit significant inhibition on both 2,3- and 2,6-sialyltransferases. © 2001 Published by Elsevier Science Ltd.

Sialic acids play an important role in a variety of biological processes.¹ They are usually attached to the terminal positions of glycoproteins, glycolipids and oligosaccharides. Of more than 100 different sialic acids, *N*-acetylneuraminic acid (NeuAc) is the most abundant one.² The sugar-nucleotide CMP-NeuAc **1** (Fig. 1) is the key substrate for biosynthesis of sialylated glycoconjugates in which **1** is transferred by sialyltransferases to an acceptor hydroxyl group in a variety of substrates including polysialic acids, glycoproteins and gangliosides.³ These glycosylation patterns constitute important binding determinants for various cell-cell interactions which include masking of trypanosomal immunogenicity, viral infection and replication, and cell adhesion.⁴ Therefore, development of potent and selective inhibitors of sialyltransferases may be useful in a variety of biochemical applications. However, only a few potent inhibitors of sialyltransferases have so far been developed.⁵ We have previously reported the solvolytic behavior and enzymology of **1**,

as characterized by kinetic isotope effects which strongly support an oxocarbenium ion-like transition state structure **2** for both solvolysis and the sialyltransferase catalyzed reactions.⁶ According to this model, positive charge is accumulated at C-1' and O-1' and the carboxylate group approaches coplanarity with the oxocarbenium ion plane. A common strategy often used to design inhibitors of glycosidases and/or glycosyltransferases is to mimic the electronic charge distribution of a proposed transition state.⁷ On the other hand, we noted that in addition to the positive charge and the coplanarity developed in **2**, the increased distance between the leaving CMP group and C-1' might be another useful factor for inhibitor design. As a test for this distinct concept, we designed compound **3a**, in which the conjugated carboxylate group mimics the oxocarbenium ion coplanarity in transition state **2**, and moreover, the CMP group attached to the bicyclic structure is held at a distance to mimic a late transition state for bond cleavage. Here we wish to report the




Figure 1.

Keywords: transition states; inhibitors; glycosyltransferases; sialyltransferases; synthesis.

* Corresponding author. Tel.: (352) 392-9859; fax: (352) 846-2095; e-mail: horen@chem.ufl.edu

synthesis and inhibitory activities of compounds **3a** and **3b** (diastereoisomer of **3a**).


We envisioned that the bicyclic structure of **3a** could be established by Meinwald rearrangement of norbornadiene **4**.⁸ With this in mind, we initiated a synthetic sequence, as shown in Scheme 1. Meinwald rearrangement of norbornadiene **4** with *m*-chloroperoxybenzoic acid and subsequent reduction with sodium borohydride gave racemic 6-*endo*-hydroxymethyl bicyclo-[3.1.0]hex-2-ene. Protection using *tert*-butyldimethylsilyl chloride or *tert*-butyldiphenylsilyl chloride in the presence of imidazole proceeded in 85–90% yields. Hydroboration–oxidation furnished the desired alcohol **5a** and its regioisomer **11a** in high yields (**5a**:**11a** ≈ 5:2, by NMR spectroscopy).⁹ The ratio of diastereomers produced by hydroboration was insensitive to the *O*-protecting group. Stereoisomers **5a**/**11a** or **5b**/**11b** could be separated by careful column chromatography. Oxidation of **5a** or **5b** with chromium trioxide–pyridine gave ketone **6a** (78%) or ketone **6b** (86%), respectively. Alternatively, a mixture of **5b**/**11b** was used for the oxidation reaction to give the desired ketone **6b**, which could be easily separated from its regioisomer by flash column chromatography. Reaction of ketone **6b** with trifluoromethanesulfonic anhydride using 2,6-di-*tert*-butyl-4-methylpyridine as a base afforded vinyl triflate **7** in 69% yield. Palladium-catalyzed carbonylation of **7** in methanol proceeded smoothly to form the unsaturated ester **8** in 80% yield.¹⁰ Deprotection of **8** with tetrabutylammonium fluoride (TBAF) gave the key intermediate **9** in 85% yield.

Cytidine-2',3'-di-*O*-acetyl-4-*N*-acetyl-5'-(*N,N*-diisopropyl-2-cyanoethyl)-phosphoramidite was prepared from the triacetyl cytidine^{11a} by the literature method.^{11c} We found that a more facile synthesis of the triacetyl cytidine could be carried out with the following one-pot sequence. Selective protection of the 5'-hydroxyl group

of *N*-acetyl-cytidine^{11b} with 4,4'-dimethoxytrityl chloride in pyridine, followed by acetylation of the 2',3'-hydroxyl groups with acetic anhydride in pyridine and deprotection of the 5'-hydroxyl group with 90% aqueous acetic acid, gave the required triacetate in 41% overall yield. The coupling of **9** with the cytidine 5'-phosphoramidite in the presence of tetrazole, followed by oxidation with *tert*-butyl hydroperoxide and base-catalyzed removal of the cyanoethyl group gave a diastereomeric mixture of **10a** and **10b**. Saponification of **10a**/**10b** with sodium methoxide in methanol–water afforded a mixture of **3a** and **3b** (1:1 by NMR), which was purified by anion-exchange HPLC (NH₄HCO₃–MeOH–H₂O buffer as eluent).¹² Our efforts to separate the diastereoisomers **3a** and **3b** were unsuccessful, so the mixture of **3a**/**3b** was used for the inhibition studies.

The inhibitory effects of **3a**/**3b** on rat 2,3- and 2,6-sialyltransferases were investigated with the use of radiolabeled [9-³H] CMP-NeuAc as a donor substrate. The acceptor sugars employed were lactose (for 2,3-sialyltransferase) and lacNac (for 2,6-sialyltransferase). The results show that **3a**/**3b** are competitive inhibitors of both 2,3- and 2,6-sialyltransferases, and the *K*_is were estimated to be 10 and 20 μM for 2,3- and 2,6-sialyltransferases, respectively. These results provide further impetus for development of new analogs that incorporate additional features of the enzyme-bound transition state.

In summary, we report the design and synthesis of a new class of sialyltransferase inhibitors which mimic transition state geometry. The key synthetic steps involve a Meinwald rearrangement and a palladium-catalyzed carbonylation reaction. Despite lacking some of the structural features (e.g. C6–C9 glycerol side chain) of the natural sialyltransferase substrate, CMP-NeuAc, the designed inhibitors **3a**/**3b** showed significant inhibition on both 2,3- and 2,6-sialyltransferases.



Scheme 1. Reagents and conditions: (a) (i) *m*-CPBA; (ii) NaBH₄; (iii) TBDMSCl or TBDPSCl, imidazole. (b) (i) BH₃·SMe₂; (ii) H₂O₂, NaOH, 90–95%. (c) CrO₃, pyridine, 78% for **6a**; 86% for **6b**. (d) Tf₂O, 2,6-di-*tert*-butyl-4-methylpyridine, 69%. (e) Pd(OAc)₂, PPh₃, Et₃N, MeOH, CO, DMF, rt, 80%. (f) TBAF, THF, 85%. (g) (i) Cytidine-2',3'-di-*O*-acetyl-4-*N*-acetyl-5'-(*N,N*-diisopropyl-2-cyanoethyl)-phosphoramidite, 1*H*-tetrazole, CH₂Cl₂; (ii) *t*-BuOOH; (iii) Et₃N, CH₂Cl₂, 51% for three steps. (h) (i) NaOMe, MeOH–H₂O; (ii) HPLC (MonoQ, NH₄HCO₃–MeOH–H₂O); (iii) desalting with Amberlite IR-120, 30%.

We expect that analogs of **3a/3b** will exhibit more potent and selective inhibition on sialyltransferases, and may be extended to other glycosyltransferases.

Acknowledgements

We wish to thank the University of Florida and National Science Foundation (CAREER Award MCB-9501866 to B.A.H.) for this work.

References

- (a) Rosenberg, A. *Biology of Sialic Acids*; Plenum: New York, 1995; (b) Reutter, W.; Stasche, R.; Stehling, P.; Baum, O. In *Glycosciences*; Gabius, H. J.; Gabius, S., Eds.; Chapman & Hall: Weinheim, 1997; pp. 245–259.
- Gottschalk, A. *Nature* **1951**, *167*, 845.
- (a) Harduin-Lepers, A.; Recchi, M. A.; Delannoy, P. *Glycobiology* **1995**, *5*, 741; (b) Varki, A. *Glycobiology* **1992**, *2*, 25; (c) Reglero, A.; Rodriguez-Aparicio, L. B.; Lueng, J. M. *Int. J. Biochem.* **1993**, *11*, 1517; (d) Hayes, B. K.; Varki, A. *J. Biol. Chem.* **1993**, *268*, 16155.
- (a) Lowe, J. B. In *Molecular Glycobiology*; Fucuda, M.; Hindsgaul, O., Eds.; Oxford University Press: New York, 1994; pp. 163–205; (b) Powell, L. D.; Varki, A. *J. Biol. Chem.* **1995**, *270*, 14243; (c) Crocker, P. R.; Kelm, S.; Hartnell, A.; Freeman, S.; Nath, D.; Vinson, M.; Mucklow, S. *Biochem. Soc. Trans.* **1996**, *24*, 150.
- (a) Schaub, C.; Muller, B.; Schmidt, R. R. *Glycoconjugate J.* **1998**, *15*, 345; (b) Muller, B.; Schaub, C.; Schmidt, R. R. *Angew. Chem., Int. Ed.* **1998**, *37*, 2893; (c) Amann, F.; Schaub, C.; Muller, B.; Schmidt, R. R. *Chem. Eur. J.* **1998**, *4*, 1106.
- (a) Horenstein, B. A.; Bruner, M. J. *Am. Chem. Soc.* **1996**, *118*, 10371; (b) Horenstein, B. A. *J. Am. Chem. Soc.* **1997**, *119*, 1101; (c) Bruner, M.; Horenstein, B. A. *Biochemistry* **1998**, *37*, 289; (d) Horenstein, B. A.; Bruner, M. *Biochemistry* **2000**, *39*, 2261.
- (a) Sinnott, M. L. *Chem. Rev.* **1990**, *90*, 1171; (b) McCarter, J. D.; Withers, S. G. *Curr. Opin. Struct. Biol.* **1994**, *4*, 885.
- Gilbert, J. C.; Smith, K. R. *J. Org. Chem.* **1976**, *41*, 3883.
- No attempt was made to determine the stereochemistry of the hydroxyl group relative to the cyclopropane ring, but it was assumed that the borane attack occurred from the less hindered side and no change in configuration took place during the peroxide oxidation.
- Cacchi, S.; Morera, E.; Ortar, G. *Tetrahedron Lett.* **1985**, *26*, 1109.
- (a) Zielinski, W. S.; Smrt, J.; Beranek, J. *Coll. Czech. Chem. Commun.* **1974**, *39*, 3560; (b) Watanabe, K. A.; Fox, J. J. *Angew. Chem., Int. Ed.* **1966**, *6*, 579; (c) Kajihara, Y.; Ebata, T.; Koseki, K.; Kodama, H.; Matsushita, H.; Hashimoto, H. *J. Org. Chem.* **1995**, *60*, 5732.
- Selected data for **9**: ^1H NMR (300 MHz, CD_3Cl) δ 6.75 (m, 1H), 3.71 (s, 3H), 3.53 (m, 1H), 3.36 (m, 1H), 2.76 (m, 1H), 2.45 (m, 1H), 2.20 (m, 1H), 1.89 (m, 1H), 1.48 (m, 1H), 1.38 (bs, 1H); ^{13}C NMR (75 MHz, CD_3Cl) δ 164.87, 141.61, 135.68, 56.31, 51.39, 31.14, 28.88, 24.10, 21.38; HRMS calcd for $\text{C}_9\text{H}_{13}\text{O}_3$ (M^++H): 169.0865; found: 169.090. For **3a/3b**: ^1H NMR (300 MHz, D_2O) δ 7.75 (d, $J=7.62$ Hz, 1H), 6.29 (bs, 1H), 5.88 (d, $J=7.62$ Hz, 1H), 5.75 (m, 1H), 4.45 (m, 3H), 3.93 (m, 1H), 3.83 (m, 1H), 3.58 (m, 1H), 3.44 (m, 1H), 2.45 (m, 1H), 2.20–2.18 (m, 2H), 1.69 (m, 1H), 1.28 (m, 1H); ^{13}C NMR (75 MHz, D_2O) δ 181.87, 173.91, 166.47, 158.12, 142.10, 141.61, 137.61, 96.82, 89.63, 89.52, 83.01, 74.46, 69.70, 64.46, 61.68, 31.96, 28.83, 23.65, 21.01; HRMS calcd for $\text{C}_{17}\text{H}_{21}\text{N}_3\text{O}_{10}$ P ($\text{M}^+-2\text{Na}^++\text{H}$): 458.0965; found: 458.087.